Late Stage

Evidence developed and ready to seek procurement

Innovators with market ready products may not be aware of the multiple different pathways to successful adoption, and how they differ according evidentiary requirements, the time and financial resources required, and the priorities of the decision makers.

ASSESS provides innovators with access to experts who can advise on the appropriate procurement pathway, and the development of the value proposition, evidence dossier and business case to match the decision maker’s requirements and priorities.

Learn more
team
Photo by AbsolutVision on Unsplash
How We Do It

Analytic approach to informing foundational decisions

At each stage of the Commercialization Journey, life sciences innovators have key questions, and analytic and decision support needs, that can be answered and provided by those with expertise in health technology assessment and health economics.

team
Photo by David Walker on Unsplash

Stage based insights and methods

Insights help to inform strategy and focus evidence generation activities on those that are the most valuable, and analyses and evidence generated support communication with investors, end users and payers.

ASSESS and a global network of experts bring methods and insights from health technology assessment and economic modelling to help innovative companies make informed strategic decisions early in technology development. Innovators at the Late Stage can have decisions informed by economic analysis of trial data, payer submission preparation, and generation of a real-world evidence development plan (collectively the technology Procurement Case).

Economic Analysis of Trial Data

Data collected from trial can be analyzed to demonstrate the economic value of technology when implemented into care pathways.

This analysis supports decision makers to understand technology impact on:

  • Healthcare resource utilization/costs
  • Health-related quality of life
  • Health care budgets over time

Analysis of trial data can determine whether a technology is considered cost-effective, and inform its value-based price.

Market Segmentation Patient Target Calculation Market Sizing
team
Photo by UX Indonesia on Unsplash
team

Health Economic Payer Submission

Submission of dossiers to payers for them to consider procurement requires analyses and evidence on the economic impact of health care technology for the proposed technology usage.

Submission packages can be prepared to describe the evidence for technology cost-effectiveness, and include a budget impact analysis to inform decision-making.

  • Trial Objectives
  • Implementation Strategies
  • Study Design
  • Outcome Measures

Real World Evidence (RWE) Development Plan

It in increasingly common that data collected from trial of technology is not able to eliminate uncertainty about how the technology will perform in routine clinical practice.

Payers increasingly are interested in on-market data collection that represents the outcomes achieved with technology use in real world settings.

An RWE Development Plan describes when and how data is to be collected, how it will be analyzed, and what decisions will be made on the basis of the results. The Plan:

  • Can permit procurement despite remaining uncertainty
  • Reduces risk for payers with pre-specified data collection/analysis and decisions that will be made
  • Improves ability to report on the economic value of technology in routine practice, supporting scale and spread
Market Segmentation Patient Target Calculation Market Sizing
team
Testimonials

What our clients say

Careteam

“We are extremely satisfied with the work done and have already recommended the service to others.

This program has been invaluable to us, I can't say enough to recommend it - this kind of evidence is vital to digital health sales and incredibly hard to find. We plan to include the service in major research projects in the future to demonstrate the economic impact of our interventions.”

Rob Attwell
COO
Tenomix

“The economic evaluation that was conducted helped with initial conversations with our investors and it ultimately led to the closure of our first financing round.

The model conducted by the ASSESS team also really gave my team and I a great starting point to truly understand the complete economics behind the problem we are solving and what types of clinical studies that we need to build in order to demonstrate the economic value proposition of the technology.”

Saumik Biswas
CEO, Founder
Greenspace

“Our team was very happy with the level of thoroughness and rigor of the work and deliverables from the ASSESS team, as well as their communication. We would recommend the service to other organizations given the ease of working with the ASSESS team and the rigor of their work.”

Tanya Scarapicchia
Proton

“We enjoyed working with and recommend ASSESS. They helped us to complete an early economic analysis, including a variety of sensitivity analyses, to assist us to demonstrate that our product is extremely cost effective in our target population.”

Rory St. Clair
VP Operations

Contact Us

Contact us to learn more about how insights from ASSESS can help your organization make informed strategic decisions that help maximize commercial success of technology in development.

Let's talk